The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression

Nature Communications

Volumn 7, Issue , 2016, Pages

  Niknafs, Yashar S ^a,b   Han, Sumin ^b   Ma, Teng ^b,c   Speers, Corey ^b   Zhang, Chao ^b   Wilder Romans, Kari ^b   Iyer, Matthew K ^a,d   Pitchiaya, Sethuramasundaram ^a   Malik, Rohit ^a   Hosono, Yasuyuki ^a   Prensner, John R ^a   Poliakov, Anton ^a   Singhal, Udit ^a,b   Xiao, Lanbo ^a   Kregel, Steven ^a   Siebenaler, Ronald F ^a   Zhao, Shuang G ^b   Uhl, Michael ^e   Gawronski, Alexander ^f   Hayes, Daniel F ^b,g   Pierce, Lori J ^b   Cao, Xuhong ^a,b   Collins, Colin ⁱ   Backofen, Rolf ^e   Sahinalp, Cenk S ^f,h,i   Rae, James M ^b,g   Chinnaiyan, Arul M ^a,b,g   Feng, Felix Y ^a,b   more..

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^d University of Freiburg ^*  (United States)

^e UNIVERSITY OF FREIBURG   (Germany)

^f SIMON FRASER UNIVERSITY   (Canada)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h INDIANA UNIVERSITY   (United States)

ⁱ VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; LONG UNTRANSLATED RNA; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

CANCER; DISEASE TREATMENT; GENE; GENETIC ANALYSIS; MOLECULAR ANALYSIS; RNA; TUMOR;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DSCAM AS1 GENE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MCF 7 CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BREAST TUMOR; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN; GENETICS; METABOLISM; TUMOR CELL LINE; TUMOR INVASION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASM INVASIVENESS; RECEPTORS, ESTROGEN; RNA, LONG NONCODING; TAMOXIFEN;

EID: 84989244698     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12791     Document Type: Article

References (70)

1. Prensner, J. R. & Chinnaiyan, A. M. The Emergence of lncRNAs in Cancer Biology. Cancer Discov. 1, 391-407 (2011).
2. Ulitsky, I. & Bartel, D. P. LincRNAs: Genomics, evolution, and mechanisms. Cell 154, 26-46 (2013).
3. Prensner, J. R. et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat. Biotechnol. 29, 742-749 (2011).
4. Prensner, J. R. et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat. Genet. 45, 1392-1398 (2013).
5. Huarte, M. et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 142, 409-419 (2010).
6. Gupta, R. A. et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 1071-1076 (2010).
7. Iyer, M. K. et al. The landscape of long noncoding RNAs in the human transcriptome. Nat. Genet. 47, 199-208 (2015).
8. Cancer Genome Atlas Research, N. et al. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2015).
9. Sun, M., Gadad, S. S., Kim, D. S. & Kraus, W. L. Discovery, annotation, and functional analysis of long noncoding RNAs controlling cell-cycle gene expression and proliferation in breast cancer cells. Mol. Cell 59, 698-711 (2015).
10. Sotiriou, C. et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100, 10393-10398 (2003).
11. Haque, R. et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol. Biomarkers Prev. 21, 1848-1855 (2012).
12. Carroll, J. S. et al. Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. 38, 1289-1297 (2006).
13. Ross-Innes, C. S. et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389-393 (2012).
14. Robinson, D. R. et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446-1451 (2013).
15. Toy, W. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439-1445 (2013).
16. Osborne, C. K. & Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 62, 233-247 (2011).
17. Qiu, J.-J. et al. Expression and clinical significance of estrogen-regulated long non-coding RNAs in estrogen receptor a-positive ovarian cancer progression. Oncol. Rep. 31, 1613-1622 (2014).
18. Chakravarty, D. et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat. Commun. 5, 5383 (2014).
19. Bhan, A. et al. Antisense transcript long noncoding RNA (lncRNA) HOTAIR is transcriptionally induced by estradiol. J. Mol. Biol. 425, 3707-3722 (2013).
20. Miano, V. et al. Luminal long non-coding RNAs regulated by estrogen receptor alpha in a ligand-independent manner show functional roles in breast cancer. Oncotarget 7, 3201-3216 (2016).
21. Hah, N. et al. A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. Cell 145, 622-634 (2011).
22. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
23. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
24. Robinson, D. R. et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat. Med. 17, 1646-1651 (2011).
25. Wang, L. et al. CPAT: Coding-potential assessment tool using an alignment-free logistic regression model. Nucleic Acids Res. 41, 1-7 (2013).
26. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
27. Rhodes, D. R. et al. ONCOMINE: a cancer microarray database and integrated data-mining platform1. Neoplasia 6, 1-6 (2004).
28. Koboldt, D. C. et al. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
29. Zhao, H. et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol. Biol. Cell 15, 2523-2536 (2004).
30. Desmedt, C. et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14, 5158-5165 (2008).
31. Ivshina, A. V. et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 66, 10292-10301 (2006).
32. Loi, S. et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol. 25, 1239-1246 (2007).
33. Lu, X. et al. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res. Treat. 108, 191-201 (2008).
34. Schmidt, M. et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 68, 5405-5413 (2008).
35. van t Veer L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-536 (2002).
36. Wang, Y. et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679 (2005).
37. Boersma, B. J. et al. A stromal gene signature associated with inflammatory breast cancer. Int. J. Cancer 122, 1324-1332 (2008).
38. Kao, K.-J., Chang, K.-M., Hsu, H.-C. & Huang, A. T. Correlation of microarraybased breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11, 143 (2011).
39. Symmans, W. F. et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J. Clin. Oncol. 28, 4111-4119 (2010).
40. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
41. Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606-11611 (2003).
42. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
43. Kim, J. H., Hahm, B., Kim, Y. K., Choi, M. & Jang, S. K. Protein-protein interaction among hnRNPs shuttling between nucleus and cytoplasm. J. Mol. Biol. 298, 395-405 (2000).
44. Liu, X. & Mertz, J. E. HnRNP L binds a cis-acting RNA sequence element that enables intron- independent gene expression. Genes Dev. 9, 1766-1780 (1995).
45. Hui, J., Stangl, K., Lane, W. S. & Bindereif, A. HnRNP L stimulates splicing of the eNOS gene by binding to variable-length CA repeats. Nat. Struct. Biol. 10, 33-37 (2003).
46. Rothrock, C. R., House, A. E. & Lynch, K. W. HnRNP L represses exon splicing via a regulated exonic splicing silencer. EMBO J. 24, 2792-2802 (2005).
47. Hung, L.-H. et al. Diverse roles of hnRNP L in mammalian mRNA processing: a combined microarray and RNAi analysis. RNA 14, 284-296 (2008).
48. Rossbach, O. et al. Crosslinking-immunoprecipitation (iCLIP) analysis reveals global regulatory roles of hnRNP L. RNA Biol. 11, 146-155 (2014).
49. Hofacker, I. L. Vienna RNA secondary structure server. Nucleic Acids Res. 31, 3429-3431 (2003).
50. Mouridsen, H. et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med. 361, 766-776 (2009).
51. Winer, E. P. et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. 23, 619-629 (2005).
52. Xue, X. et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene 35, 2746-2755 (2015).
53. Godinho, M., Meijer, D., Setyono-Han, B., Dorssers, L. C. J. & Van Agthoven, T. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells. J. Cell. Physiol. 226, 1741-1749 (2011).
54. Poliakov, A. et al. Large-scale label-free quantitative proteomics of the pea aphid-Buchnera symbiosis. Mol. Cell. Proteomics 10, M110.007039 (2011).
55. Vizcaino, J., Deutsch, E. & Wang, R. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat. Biotechnol. 32, 223-226 (2014).
56. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
57. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
58. Karolchik, D. et al. The UCSC Genome Browser database: 2014 update. Nucleic Acids Res. 42, 764-770 (2014).
59. Qin, Z. S. et al. HPeak: an HMM-based algorithm for defining read-enriched regions in ChIP-Seq data. BMC Bioinformatics 11, 369 (2010).
60. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
61. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562-578 (2012).
62. Ma, X.-J. et al. Gene expression profiles of human breast cancer progression. Proc. Natl Acad. Sci. USA 100, 5974-5979 (2003).
63. McLendon, R. et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
64. van t Veer L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-536 (2002).
65. Maher, C. A. et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc. Natl Acad. Sci. USA 106, 12353-12358 (2009).
66. Levin, J. Z. et al. Comprehensive comparative analysis of strand-specific RNA sequencing methods. Nat. Methods 7, 709-715 (2010).
67. Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739-1740 (2011).
68. Maticzka, D., Lange, S. J., Costa, F. & Backofen, R. GraphProt: modeling binding preferences of RNA-binding proteins. Genome Biol. 15, R17 (2014).
69. Raj, A., van den Bogaard, P., Rifkin, S. a., van Oudenaarden, A. & Tyagi, S. Imaging individual mRNA molecules using multiple singly labeled probes. Nat. Methods 5, 877-879 (2008).
70. Pitchiaya, S., Androsavich, J. R. & Walter, N. G. Intracellular single molecule microscopy reveals two kinetically distinct pathways for microRNA assembly. EMBO Rep. 13, 709-715 (2012).